FindTrial
Sign In

Trifluridine Tipiracil

DRUG2 trials

Sponsors

University of Campania Luigi Vanvitelli, Oncolytics Biotech

Conditions

Anal Cancer MetastaticMetastatic Colon CancerPancreatic Cancer MetastaticSquamous Cell Carcinoma of the Anus Stage UnspecifiedUnresectable Pancreatic Carcinoma

Phase 1

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
RecruitingNCT07280377
Oncolytics BiotechAnal Cancer Metastatic, Pancreatic Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified +1
Start: 2021-10-27End: 2028-12-31Target: 122Updated: 2025-12-12

Phase 2

Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial
CompletedNCT05468892
University of Campania Luigi VanvitelliMetastatic Colon Cancer
Start: 2019-10-29End: 2022-06-30Updated: 2024-02-01

Related Papers

Anti-EGFR Rechallenge in Patients With Refractory ctDNA <i>RAS/BRAF</i> wt Metastatic Colorectal Cancer
JAMA Network Open2024-04-0937 citations
Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory <i>RAS</i> Wild-Type Metastatic Colorectal Cancer
JAMA Oncology2023-05-1852 citations
Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II clinical trial.
Journal of Clinical Oncology2023-01-244 citations